APA (7th ed.) Citation

Kim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz, Laia Solé-Feu, & José-Carlos A. (2024). Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis'". Adis, Springer Healthcare.

Chicago Style (17th ed.) Citation

Kim Rand, Juan Manuel Ramos-Goñi, Bülent Akmaz, Laia Solé-Feu, and José-Carlos A. Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Vs. Dupilumab in Moderate to Severe Atopic Dermatitis'". Adis, Springer Healthcare, 2024.

MLA (9th ed.) Citation

Kim Rand, et al. Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Vs. Dupilumab in Moderate to Severe Atopic Dermatitis'". Adis, Springer Healthcare, 2024.